ApoE

Population-based longitudinal study shows amyloid accumulation begins ~15–20 years before estimated AD onset; accumulation rate decelerates near symptom onset once a plateau is reached, suggesting a narrow therapeutic window for anti-amyloid interventions.

Donanemab (anti-pyroglutamate-Aβ MAb) shows positive primary endpoint in early symptomatic AD with low/medium tau PET burden. Tau PET stratification meaningfully modifies treatment effect — high-tau subgroup shows attenuated benefit. ARIA-E rate ~24%; APOE4-dose-dependent.

Donanemab (anti-N3pG Aβ antibody) in Phase II TRAILBLAZER-ALZ reduced amyloid plaque load to near-zero in a majority of participants and slowed clinical decline on the iADRS by 32% versus placebo at 76 weeks in early symptomatic AD.

Anti-amyloid immunotherapy ARIA (amyloid-related imaging abnormalities) — edema (ARIA-E) and microhemorrhage (ARIA-H) — occurs in 15-40% of APOE4 carriers receiving high-dose anti-Aβ antibodies; radiological characterization and risk stratification framework published to guide clinical management.

APOE4 carrier status increases the importance of ARIA risk stratification for anti-amyloid antibody treatment.

AHEAD A3 (NCT04468659) is a Phase III preclinical-AD lecanemab trial in cognitively-unimpaired adults with intermediate amyloid; eligibility uses APOE genotype stratification, with the 2022 SAP amendment refining APOE4-positive arm allocation in line with APOE4-specific BBB/pericyte evidence.

CLARITY-AD lecanemab eligibility required APOE genotyping with specific dosing protocols for APOE4 homozygotes after early ARIA-E rates exceeded 25% in that subgroup; bapineuzumab APOE4 ARIA-E precedent informed design.

Roche-Denali Brain Shuttle gantenerumab (Trontinemab / RG6102, NCT04374253) program scope reflects BBB-transcytosis-as-delivery-target architecture; following Montagne 2020 APOE4-stratified BBB evidence, program decision-making prioritizes APOE4-stratified PK/PD readouts and BBB-permeability biomarker integration.

FDA labeling for lecanemab (Leqembi) and donanemab (Kisunla) requires APOE genotyping prior to initiation due to APOE4-dose-dependent ARIA-E risk; regulatory framework anchored in earlier MAb-class evidence including bapineuzumab.

AHEAD A3 (NCT04468659) lecanemab preclinical-AD trial protocol mandates APOE genotyping and stratified arm allocation; eligibility design directly references prior anti-Aβ MAb ARIA-E APOE4-dose-dependence including bapineuzumab 302.

Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis.

Lecanemab appropriate use recommendations for clinical practice in the UK. — Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4)...

Efficacy and <i>APOE</i> ε4-stratified risk of donanemab in Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials.

Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic. — Lecanemab and donanemab are the first anti-Aβ treatments to receive approval in Europe. Eligibility criteria are strict, eg., APOE ε4/4 carriers are...

CRISPR editing of miR-33 restores ApoE lipidation and amyloid-β metabolism in ApoE4 sporadic Alzheimer's disease. — Sporadic Alzheimer's disease (sAD) is marked by dysregulated lipid metabolism, prominently involving apolipoprotein E (ApoE). MicroRNA-33 (miR-33) has emerged as a key regulator of lipid homeostasis,...

Relationship between <i>APOE</i> Genotype Status and Imaging Features in Patients with Alzheimer Disease Being Considered for Antiamyloid β Therapy.

Can APOE4-specific risk models prospectively identify patients whose ARIA risk outweighs expected anti-amyloid benefit?

Which public patient-level dataset can jointly inspect amyloid clearance, tau movement, ARIA events, APOE4 status, and cognitive trajectory after anti-amyloid treatment?

Bapineuzumab (anti-Aβ monoclonal) failed primary endpoints in two Phase III trials in mild-moderate Alzheimer's. ARIA-E vasogenic edema rate was elevated in APOE4 carriers, foreshadowing the BBB-permeability / APOE4 axis later articulated by Montagne 2020.

Lecanemab (anti-protofibril Aβ MAb) shows modest but statistically significant slowing of cognitive decline (CDR-SB ~0.45 point benefit at 18 months) in early symptomatic AD with PET-confirmed amyloid. First clearly positive Phase III for amyloid-cascade-as-drug-target — confidence updates upward in early-stage AD...

Aducanumab (anti-Aβ monoclonal) reduces brain amyloid plaque burden dose- and time-dependently in mild-AD patients (Phase Ib PRIME trial); pilot signal of cognitive benefit at higher doses, with ARIA-E rate APOE4-dose-dependent. The Phase Ib that motivated ENGAGE/EMERGE.